Table 1. Anthropometric and clinical characteristics of patients.
| All (n = 80) | Carotid plaque |
P value | ||
|---|---|---|---|---|
| No (n = 47) | Yes (n = 33) | |||
| Male gender, n (%) | 44 (55.0%) | 23 (48.9%) | 21 (63.6%) | 0.235 |
| Age (years) | 53.0 ± 10.1 | 50.1 ± 9.7 | 57.2 ± 9.3 | 0.002 |
| PsA characteristics | ||||
| PsA disease duration (years) | 14.3 ± 7.2 | 12.5 ± 6.9 | 16.9 ± 6.8 | 0.006 |
| Tender joint count (0–68) | 0 (0–3) | 0 (0–3) | 0 (0–3) | 0.783 |
| Swollen joint count (0–66) | 0 (0–1) | 0 (0–1) | 0 (0–1) | 0.359 |
| Damaged joint count (0–68) | 2 (0–6) | 2 (0–6) | 2 (1–8) | 0.273 |
| VAS Pain (0–100) | 30 (10–58) | 30 (20–50) | 30 (10–60) | 0.844 |
| Patients’ global (0–100) | 50 (20–60) | 50 (20–60) | 50 (20–60) | 0.833 |
| Physicians’ global (0–100) | 20 (8–40) | 20 (6–37) | 20 (10–40) | 0.746 |
| PASI (0–72) | 2.2 (0.8–6.4) | 2.7 (0.9–6.5) | 1.8 (0.5–5.4) | 0.490 |
| HAQ (0–3) | 0.19 (0–0.63) | 0.13 (0–0.50) | 0.38 (0–0.88) | 0.976 |
| MDA, n(%) | 16 (20.0%) | 10 (21.3%) | 6 (18.2%) | 0.784 |
| ESR (mm/1st hr) | 15 (7–28) | 16 (7–31) | 14 (6–28) | 0.899 |
| CRP (mg/dl) | 0.3 (0.1–0.7) | 0.3 (0.1–0.6) | 0.3 (0.1–0.8) | 0.799 |
| CV and osteoporosis risk factors | ||||
| Body weight (kg) | 68.5 ± 13.6 | 68.5 ± 15.3 | 68.7 ± 10.9 | 0.944 |
| BMI (kg/m2) | 25.6 ± 4.1 | 25.8 ± 4.5 | 25.4 ± 3.5 | 0.675 |
| Systolic BP (mmHg) | 129 ± 17 | 128 ± 15 | 130 ± 19 | 0.614 |
| Diastolic BP (mmHg) | 82 ± 11 | 82 ± 10 | 81 ± 12 | 0.593 |
| Hypertension, n(%) | 46 (57.5%) | 26 (55.3%) | 20 (60.6%) | 0.721 |
| Diabetes, n(%) | 16 (20.0%) | 7 (14.9%) | 9 (27.3%) | 0.151 |
| Hyperlipidemia, n(%) | 21 (26.3%) | 9 (19.1%) | 12 (36.4%) | 0.085 |
| Metabolic syndrome, n(%) | 23 (29.1%) | 15 (32.6%) | 8 (24.2%) | 0.469 |
| Framingham 10-year CVD risk > 10%, n(%) | 37 (46.3%) | 16 (34.0%) | 21 (63.6%) | 0.013 |
| Cardiovascular event, n(%) | 9 (11.3%) | 2 (4.3%) | 7 (21.2%) | 0.029 |
| Total cholesterol (mmol/L) | 5.0 ± 0.8 | 5.0 ± 0.8 | 5.0 ± 0.8 | 0.878 |
| HDL cholesterol (mmol/L) | 1.4 ± 0.4 | 1.4 ± 0.4 | 1.4 ± 0.4 | 0.841 |
| Triglycerides (mmol/L) | 1.5 ± 0.9 | 1.6 ± 1.0 | 1.4 ± 0.6 | 0.572 |
| Fasting glucose (mmol/L) | 5.6 ± 1.7 | 5.7 ± 1.9 | 5.5 ± 1.4 | 0.542 |
| Post-menopause women, n(%) | 22 (61.1%) | 14 (58.3%) | 8 (66.7%) | 0.727 |
| Current smoker, n(%) | 9 (11.3%) | 5 (10.6%) | 4 (12.1%) | 0.999 |
| Current drinker, n(%) | 1 (1.3%) | 1 (2.1%) | 0 (0%) | 0.999 |
| Parent history of fracture, n(%) | 7 (8.8%) | 5 (10.6%) | 2 (6.1%) | 0.694 |
| History of fracture, n(%) | 7 (8.8%) | 4 (8.5%) | 3 (9.1%) | 0.999 |
| Current medications, n (%) | ||||
| Anti-hypertensive | 44 (55.0%) | 25 (53.2%) | 19 (57.6%) | 0.698 |
| Statins | 14 (17.5%) | 5 (10.6%) | 9 (27.3%) | 0.046 |
| NSAIDs | 34 (42.5%) | 21 (44.7%) | 13 (39.4%) | 0.525 |
| Steroids | 2 (2.5%) | 1 (2.1%) | 1 (3.0%) | 0.999 |
| DMARDs | 45 (56.3%) | 28 (59.6%) | 17 (51.5%) | 0.400 |
| Biologics | 14 (17.5%) | 8 (17.0%) | 6 (18.2%) | 0.843 |
| Biomarkers | ||||
| Detectable IL-33, n (%) | 12 (15.0%) | 8 (17.0%) | 4 (12.1%) | 0.752 |
| sST2 (ng/ml) | 9.1 ± 4.4 | 7.7 ± 3.7 | 11.2 ± 4.5 | < 0.001 |
VAS: visual analogue scale, PASI: Psoriasis Area and Severity Index, HAQ: Health Assessment Questionnaire, MDA: minimal disease activity, ESR: erythrocyte sedimentation rate, CRP: c-reactive protein, CV: cardiovascular, BMI: body mass index, BP: blood pressure, HDL: high-density lipoprotein, NSAIDs: nonsteroidal anti-inflammatory drugs, DMARDs: disease-modifying antirheumatic drugs. Values are the number (percentage) or median (interquatile range) or mean ± SD.